Literature DB >> 22083792

Forced degradation of therapeutic proteins.

Andrea Hawe1, Michael Wiggenhorn, Marco van de Weert, Joerg H O Garbe, Hanns-Christian Mahler, Wim Jiskoot.   

Abstract

The scope of this paper is to review approaches used for forced degradation (synonym, stress testing) of therapeutic proteins. Forced degradation studies play a central role in the development of therapeutic proteins, for example, for candidate selection, molecule characterization, formulation development, assay development, and comparability studies. Typical stress methods are addressed within this review, such as exposure to elevated temperatures, freeze-thawing, mechanical stress, oxidation, light, as well as various materials and devices used in the clinics during final administration. Stability testing is briefly described as far as relevant to the discussion of forced degradation studies. Whereas stability-testing requirements are defined in regulatory guidelines, standard procedures for forced degradation of therapeutic proteins are largely unavailable, except for photostability. Possible selection criteria to identify appropriate stress conditions and recommendations for setting up forced degradation studies for the different phases of development of therapeutic proteins are presented.
Copyright © 2011 Wiley Periodicals, Inc.

Mesh:

Substances:

Year:  2011        PMID: 22083792     DOI: 10.1002/jps.22812

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  43 in total

1.  Flow imaging microscopy for protein particle analysis--a comparative evaluation of four different analytical instruments.

Authors:  Sarah Zölls; Daniel Weinbuch; Michael Wiggenhorn; Gerhard Winter; Wolfgang Friess; Wim Jiskoot; Andrea Hawe
Journal:  AAPS J       Date:  2013-08-31       Impact factor: 4.009

Review 2.  Silk-based stabilization of biomacromolecules.

Authors:  Adrian B Li; Jonathan A Kluge; Nicholas A Guziewicz; Fiorenzo G Omenetto; David L Kaplan
Journal:  J Control Release       Date:  2015-09-25       Impact factor: 9.776

3.  Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.

Authors:  Thomas Spreter Von Kreudenstein; Eric Escobar-Carbrera; Paula I Lario; Igor D'Angelo; Karine Brault; John Kelly; Yves Durocher; Jason Baardsnes; R Jeremy Woods; Michael Hongwei Xie; Pierre-Alain Girod; Michael D L Suits; Martin J Boulanger; David K Y Poon; Gordon Y K Ng; Surjit B Dixit
Journal:  MAbs       Date:  2013-07-08       Impact factor: 5.857

4.  Complex Nature of Protein Carbonylation Specificity After Metal-Catalyzed Oxidation.

Authors:  Dmitry Kryndushkin; Wells W Wu; Ramesh Venna; Michael A Norcross; Rong-Fong Shen; V Ashutosh Rao
Journal:  Pharm Res       Date:  2017-02-01       Impact factor: 4.200

5.  Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions.

Authors:  Srivalli N Telikepalli; Ozan S Kumru; Cavan Kalonia; Reza Esfandiary; Sangeeta B Joshi; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2014-01-22       Impact factor: 3.534

6.  Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.

Authors:  Ranajoy Majumdar; Reza Esfandiary; Steven M Bishop; Hardeep S Samra; C Russell Middaugh; David B Volkin; David D Weis
Journal:  MAbs       Date:  2015       Impact factor: 5.857

7.  Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™.

Authors:  Karthik Pisupati; Alexander Benet; Yuwei Tian; Solomon Okbazghi; Jukyung Kang; Michael Ford; Sergei Saveliev; K Ilker Sen; Eric Carlson; Thomas J Tolbert; Brandon T Ruotolo; Steven P Schwendeman; Anna Schwendeman
Journal:  MAbs       Date:  2017-08-08       Impact factor: 5.857

8.  Nanofluidic device for continuous multiparameter quality assurance of biologics.

Authors:  Sung Hee Ko; Divya Chandra; Wei Ouyang; Taehong Kwon; Pankaj Karande; Jongyoon Han
Journal:  Nat Nanotechnol       Date:  2017-05-22       Impact factor: 39.213

9.  Rapid assessment of oxidation via middle-down LCMS correlates with methionine side-chain solvent-accessible surface area for 121 clinical stage monoclonal antibodies.

Authors:  Rong Yang; Tushar Jain; Heather Lynaugh; R Paul Nobrega; Xiaojun Lu; Todd Boland; Irina Burnina; Tingwan Sun; Isabelle Caffry; Michael Brown; Xiaoyong Zhi; Asparouh Lilov; Yingda Xu
Journal:  MAbs       Date:  2017-02-14       Impact factor: 5.857

10.  An Efficient and Rapid Method to Monitor the Oxidative Degradation of Protein Pharmaceuticals: Probing Tyrosine Oxidation with Fluorogenic Derivatization.

Authors:  Rupesh Bommana; Olivier Mozziconacci; Y John Wang; Christian Schöneich
Journal:  Pharm Res       Date:  2017-04-18       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.